Potential role of the inactivated X chromosome in ovarian epithelial tumor development

Journal of the National Cancer Institute
P C ChengL Dubeau

Abstract

Ovarian epithelial tumors can be divided into subcategories often regarded as different stages of neoplastic transformation. Cystadenomas belong to the least aggressive subgroup and are noninvasive and nonmetastatic. Ovarian tumors of low malignant potential (LMP) are intermediate between cystadenomas and carcinomas and show markedly reduced invasive and metastatic abilities. Invasion and metastasis are the hallmarks of carcinomas, which constitute the most aggressive subgroup and can be further subdivided into different grades. We performed comparative allelotype analyses of ovarian cystadenomas, LMP tumors, and carcinomas, reasoning that such analyses could provide clues about the molecular determinants of their phenotypic differences. Because we realized that allelic losses involving the X chromosome might be associated with LMP tumor development, we determined whether such losses were interstitial and whether they involved the active or the inactive X chromosome. Frequencies of loss of heterozygosity (LOH) at specific loci in every chromosomal arm were determined in 16 ovarian cystadenomas, 23 ovarian LMP tumors, 15 low-grade ovarian carcinomas, and 35 high-grade ovarian carcinomas by use of either the polymerase chain reac...Continue Reading

Citations

Jun 22, 2000·Genes, Chromosomes & Cancer·H L McDonaldC J Brown
Mar 29, 2002·International Journal of Cancer. Journal International Du Cancer·Edoardo MissiagliaAldo Scarpa
Sep 30, 2004·International Journal of Cancer. Journal International Du Cancer·Sorina Grisaru-GranovskyRachel Bar-Shavit
Oct 26, 2005·Virchows Archiv : an International Journal of Pathology·Cinzia AzzoniCesare Bordi
Jan 24, 2002·Cancer Letters·Kentaro NakayamaYuji Takebayashi
Aug 3, 2004·Nature Reviews. Cancer·Alain SpatzJean Feunteun
Feb 24, 2001·Histopathology·K M Feeley, M Wells
Mar 19, 1997·Journal of the National Cancer Institute·M WanL Dubeau
Aug 2, 2001·Journal of the National Cancer Institute·G J Gardner, M J Birrer
Oct 7, 2004·Journal of the National Cancer Institute·Dirk BrinkmannIan J Jacobs
Feb 24, 2001·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·B A Werness, G H Eltabbakh
Jun 29, 2007·Journal of Clinical Pathology·Lydia NakopoulouAntonios Keramopoulos
Apr 21, 2012·Future Oncology·Runhua LiuLizhong Wang
Oct 10, 2003·Cancer Investigation·Dezhong Joshua LiaoFazlul H Sarkar
Feb 25, 2010·PloS One·Sahar HoushdaranPeter W Laird
Mar 18, 1999·Hematology/oncology Clinics of North America·X W TongS M Freeman
Sep 21, 2007·Journal of Cellular Biochemistry·Jeremy R ChienLynn C Hartmann
May 8, 1999·The British Journal of Dermatology·J A McGrathR A Eady
Jan 23, 2004·Archives of Pathology & Laboratory Medicine·Liang ChengThomas A Gardner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.